Can I Take Reishi Mushroom with Tresiba (Insulin Degludec)?

What Is the Interaction Between Reishi Mushroom and Tresiba?

The core concern is a pharmacodynamic interaction: both Tresiba and reishi mushroom lower blood glucose through different mechanisms, and their effects add together. Tresiba is an ultra-long-acting basal insulin approved by the FDA for adults and pediatric patients with type 1 and type 2 diabetes, providing a steady glucose-lowering effect across a 24-hour dosing interval with a half-life of approximately 25 hours. [1] Reishi mushroom contains bioactive polysaccharides and triterpenes that have shown independent glucose-lowering activity in multiple preclinical models and small human trials. [2]

What "Pharmacodynamic" Means for You

A pharmacokinetic interaction would change how much of one drug your body absorbs or clears. A pharmacodynamic interaction is different: each agent acts through its own separate pathway, yet both pathways converge on the same outcome, lower blood glucose. Because the mechanisms are parallel rather than competitive, no timing adjustment (such as separating doses by two or four hours) eliminates the added effect. If reishi lowers your glucose by 10 to 15 mg/dL and your Tresiba dose is already calibrated to your baseline physiology, that additional drop may push you into the hypoglycemic range (below 70 mg/dL per the American Diabetes Association Level 1 threshold). [3]

Why Tresiba's Pharmacology Makes This Riskier Than With Shorter-Acting Insulins

Tresiba forms multi-hexameric complexes after subcutaneous injection, creating a depot that releases insulin degludec slowly into the circulation. The FDA prescribing information for Tresiba (NDA 203314) confirms a duration of action exceeding 42 hours at therapeutic doses. [1] That sustained activity window means any glucose-lowering supplement taken at virtually any point in the day overlaps with the drug's active period. Patients on shorter-acting bolus insulins at least have intermittent windows of lower insulin concentration; Tresiba users do not.

How Does Reishi Mushroom Lower Blood Glucose?

Reishi mushroom lowers blood glucose through at least three identified mechanisms: alpha-glucosidase inhibition (slowing carbohydrate digestion), beta-cell protection via polysaccharide-mediated antioxidant activity, and PPAR-gamma agonism that may improve insulin sensitivity. [2] [4]

Alpha-Glucosidase Inhibition

Several Ganoderma lucidum polysaccharide fractions have shown alpha-glucosidase inhibitory activity in vitro. [4] This mechanism mirrors that of the prescription drug acarbose (Precose). Patients who already take insulin and an alpha-glucosidase inhibitor are a known clinical group that requires careful glucose monitoring, and reishi may produce a qualitatively similar dynamic.

Polysaccharide-Mediated Beta-Cell Effects

A 2003 study published in the British Journal of Nutrition found that Ganoderma lucidum polysaccharides reduced fasting plasma glucose and restored beta-cell function in streptozotocin-induced diabetic mice, with statistically significant results (P<0.01 vs. Control). [2] While animal data cannot be directly transposed to humans taking therapeutic insulin doses, the direction of effect is consistent across multiple independent research groups.

PPAR-Gamma and Insulin Sensitization

Triterpene compounds isolated from Ganoderma lucidum, including ganoderic acids, have been shown to activate peroxisome proliferator-activated receptor gamma (PPAR-gamma), the same nuclear receptor targeted by thiazolidinediones such as pioglitazone. [5] PPAR-gamma activation improves peripheral insulin sensitivity. In someone whose Tresiba dose was set at baseline insulin sensitivity, any incremental improvement in sensitivity means the same dose now produces a larger glucose drop.

What Are the Clinical Hypoglycemia Risks?

Hypoglycemia is the primary safety concern for any person using insulin who adds a glucose-lowering supplement. The ADA defines three clinically relevant thresholds: Level 1 (glucose 54 to 70 mg/dL, actionable), Level 2 (glucose <54 mg/dL, serious), and Level 3 (severe cognitive impairment requiring external assistance). [3] All three levels are possible when supplement-driven additive effects destabilize a previously stable insulin regimen.

Frequency of Hypoglycemia in Tresiba Trials

In the BEGIN Once Long trial (N=1,030), insulin degludec produced significantly fewer confirmed hypoglycemic episodes than insulin glargine U-100 (11% rate reduction; P<0.05). [6] That relative advantage exists compared to a competitor insulin, not compared to no insulin at all. Adding a glucose-lowering supplement narrows any such safety margin. In the BEGIN Flex trial (N=687), flexible dosing of Tresiba still maintained hypoglycemia rates below insulin glargine, but the study included no supplement co-administration arm. [7]

Recognizing Hypoglycemia While on Basal Insulin

Symptoms to watch for include diaphoresis (sweating), tremor, palpitations, confusion, and in severe cases loss of consciousness. The American Diabetes Association 2024 Standards of Care recommend that all patients on insulin be counseled on hypoglycemia recognition, treatment with 15 to 20 g fast-acting carbohydrate, and when to call emergency services. [3] If you are taking reishi mushroom alongside Tresiba, reviewing this protocol with your prescriber or pharmacist is not optional, it is a basic safety step.

HealthRX Hypoglycemia Risk Staging for Tresiba + Reishi Co-Use

| Risk Category | Patient Profile | Recommended Action | |---|---|---| | Low | T2D, HbA1c >8%, no prior hypoglycemia, eating regular meals | Tell prescriber; monitor fasting glucose daily | | Moderate | T2D or T1D, HbA1c 7 to 8%, 1 to 2 hypoglycemic episodes in past 6 months | Hold reishi until prescriber reviews Tresiba dose | | High | T1D, HbA1c <7%, hypoglycemia unawareness, renal impairment | Do not add reishi without prescriber dose adjustment |

Does Reishi Mushroom Affect Blood Clotting Alongside Tresiba?

Reishi mushroom has documented antiplatelet and anticoagulant activity independent of its glucose-lowering effects. This matters most to Tresiba patients who also take warfarin, aspirin, NSAIDs, or any anticoagulant, because many people with diabetes are on one or more of these agents for cardiovascular protection.

Antiplatelet Mechanism

Ganoderma lucidum extracts inhibit ADP-induced and collagen-induced platelet aggregation in vitro. [8] A review published in the International Journal of Medicinal Mushrooms catalogued these effects across multiple Ganoderma species. [8] The clinical relevance in isolated reishi use at typical supplement doses (1 to 1.5 g dried extract per day) is uncertain, but the concern rises sharply when combined with anticoagulant drugs.

Drug Interactions With Warfarin

Case reports have documented elevated INR in patients who added Ganoderma lucidum supplements while stable on warfarin therapy. [9] If your diabetes management already includes warfarin (still used for atrial fibrillation, a condition more common in people with type 2 diabetes), adding reishi without INR monitoring is inadvisable.

Relevance to Cardiovascular Medications Common in Diabetes

The ADA 2024 Standards of Care recommend low-dose aspirin (75 to 100 mg/day) for adults with diabetes and established atherosclerotic cardiovascular disease. [3] Reishi's antiplatelet activity adds to aspirin's effect. Patients on dual antiplatelet therapy or oral anticoagulants carry a higher bleeding risk with reishi co-administration.

What Does Human Clinical Evidence Actually Show?

Human trial data for reishi mushroom in diabetes is sparse and methodologically limited. No large randomized controlled trial with insulin-using participants has been completed.

Available Human Trial Data

A 2003 Phytotherapy Research study enrolled 71 adults with type 2 diabetes not on insulin and found that Ganoderma lucidum extract (Ganopoly, 1.44 g three times daily for 12 weeks) reduced HbA1c by 0.6 percentage points vs. Placebo (P<0.05). [10] Fasting glucose fell by approximately 2.5 mmol/L (45 mg/dL). [10] These are modest but real effects in drug-naive patients. Extrapolating to someone already on basal insulin requires caution, because their glycemic baseline and variability are governed by an exogenous hormone operating on a 25-hour activity window.

A 2016 Cochrane Review Finding

A Cochrane systematic review published in 2016 (Shing et al.) evaluated Ganoderma lucidum as a treatment for type 2 diabetes across all available RCTs. [11] The reviewers concluded there was "insufficient evidence" to recommend reishi as first- or second-line treatment and noted that most trials had high risk of bias. [11] They specifically called for trials with longer follow-up, standardized extract preparation, and patient populations on background antidiabetic medications, none of which have since been published at scale.

What the Evidence Gap Means Clinically

Absence of large trial data does not mean reishi is safe alongside insulin. It means no one has systematically measured the interaction. Clinicians must therefore rely on mechanistic reasoning, small trial signals, and individual patient monitoring rather than population-level risk estimates.

Is Reishi Mushroom Safe in General?

At typical supplemental doses, reishi is generally well tolerated in short-term use. Adverse effects reported in clinical trials include dry mouth, dizziness, and gastrointestinal discomfort. [10] Hepatotoxicity has been reported with powdered reishi preparations (as opposed to water-based extracts) in case series. [12] The National Institutes of Health National Center for Complementary and Integrative Health (NCCIH) notes that reishi products vary widely in their polysaccharide and triterpene content, making dose standardization difficult. [13]

Liver Function Considerations for Tresiba Patients

Insulin degludec's prescribing information does not mandate liver function monitoring, but the FDA label notes that hepatic impairment may increase insulin sensitivity and hypoglycemia risk. [1] Patients with non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in type 2 diabetes (estimated prevalence 55 to 75% by ultrasound across large cohort studies), may face compounded risk from both the hypoglycemia pharmacodynamic interaction and any hepatotoxic potential of reishi powdered preparations. [12] [14]

Renal Impairment and Hypoglycemia Risk

The FDA label for Tresiba notes increased sensitivity to insulin in patients with renal impairment, elevating baseline hypoglycemia risk before any supplement is added. [1] The National Kidney Foundation estimates that approximately 40% of adults with diabetes have chronic kidney disease. [15] For this subgroup, any additive glucose-lowering effect from reishi carries amplified clinical consequences.

What Should You Do If You Are Already Taking Both?

Do not abruptly stop either Tresiba or reishi without guidance. Stopping basal insulin abruptly causes rapid glucose elevation that can precipitate diabetic ketoacidosis in type 1 patients and hyperglycemic hyperosmolar state in type 2 patients. [3]

Step-by-Step Clinical Guidance

1. Tell your prescriber at your next visit (or call the office before then) that you are using reishi mushroom.
2. Increase self-monitoring of blood glucose (SMBG) to at least fasting and 2-hour post-meal readings daily until your prescriber assesses whether your Tresiba dose needs adjustment.
3. Carry fast-acting glucose (glucose tablets, 4 oz orange juice) at all times while co-administering both agents.
4. If you use warfarin or aspirin, request an INR check or discuss bleeding risk with your prescriber before your next scheduled test.
5. Review the reishi product label for preparation type (water extract vs. Powdered whole mushroom), because the glucose-lowering and anticoagulant potency varies by preparation. [13]

When to Call Your Prescriber Immediately

Call your prescriber or seek urgent care if you experience: blood glucose readings below 70 mg/dL on two or more consecutive measurements, symptoms of severe hypoglycemia (confusion, inability to swallow, loss of consciousness), or unexpected bruising or prolonged bleeding while on antiplatelet or anticoagulant therapy.

Does Reishi Affect How Tresiba Is Absorbed or Cleared?

Available evidence does not suggest a pharmacokinetic interaction between reishi mushroom and insulin degludec. Insulin is cleared by receptor-mediated endocytosis in peripheral tissues and by renal proteolysis. [1] Reishi's bioactive compounds, polysaccharides and triterpene acids, are unlikely to alter these pathways in a clinically meaningful way based on current mechanistic data. [4] No in vitro cytochrome P450 data for reishi-insulin combinations appears in current PubMed-indexed literature, and Ganoderma lucidum compounds are not known to significantly inhibit or induce the primary CYP enzymes responsible for drug metabolism. [5] The interaction risk therefore remains pharmacodynamic, not pharmacokinetic.

What Do Diabetes Guidelines Say About Supplements and Insulin?

No major diabetes guideline currently endorses reishi mushroom as adjunct therapy for insulin-using patients. The ADA 2024 Standards of Care state directly: "There is no clear evidence of benefit from vitamin or mineral supplementation in people with diabetes who do not have underlying deficiencies, and routine supplementation with antioxidants such as vitamins E and C and carotene is not advised because of lack of evidence of efficacy and concern related to long-term safety." [3] While this statement targets antioxidant vitamins specifically, it reflects the ADA's broader position that supplement recommendations require strong trial evidence before patients on glucose-lowering drugs add them.

The Endocrine Society's clinical practice guidelines on diabetes management likewise do not include botanical supplements among recommended adjunct agents for patients on basal insulin therapy. [16] The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guideline for diabetes management advises clinicians to ask about all supplement use at each visit because of potential drug-supplement interactions. [17]